Company Encyclopedia
View More
name
Galecto
GLTO.US
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
1.946 T
GLTO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Galecto Inc. Files Initial Beneficial Ownership Statement Naming Fairmount Funds Management LLC

    Galecto Inc. has filed a statement with the SEC naming Fairmount Funds Management LLC as the beneficial owner. This filing is accessible via EDGAR, and the information is provided by Public Technologies using AI. The original content was published by Galecto Inc. on November 17, 2025.

    Reuters·
    US
    GLTO
    +3.39%
    Reuters·
    US
    GLTO
    +3.39%

    Galecto Inc. Files Initial Beneficial Ownership Statement for Director Bruno Julianne

    Galecto Inc. has filed an initial statement of beneficial ownership with the U.S. SEC, listing Bruno Julianne as the beneficial owner and Director. The filing is accessible via EDGAR (Ref. ID: 0001193125-25-285069).

    Reuters·
    US
    GLTO
    +3.39%
    Reuters·
    US
    GLTO
    +3.39%

    U.S. stock night market volatility: Galecto fell 4.49% in after-hours trading, with acquisition news and technical signals raising market concerns

    Galecto fell 4.49% in the night session; BeiGene rose 0.86% in the night session, with a trading volume of USD 1.57 million; Korro Bio fell 76.77% in the night session, with a trading volume of USD 308,100; Recursion Pharmaceuticals rose 0.65% in the night session, with a trading volume of USD 93,700

    Tracking Unusual Activity·
    US
    GLTO
    +3.39%
    Tracking Unusual Activity·
    US
    GLTO
    +3.39%

    GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

    Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) saw their stocks surge approximately 300% today due to company-specific news. Galecto's rally followed its acquisition of Damora Therapeutics, enhancing its oncology pipeline and securing a $285 million private placement. Movano's stock jumped after announcing a merger with Corvex, transforming it into an AI infrastructure platform. Despite these gains, both stocks are considered risky due to their penny stock status, which makes them vulnerable to volatility and manipulation. Investors are advised to proceed with caution.

    Invezz·
    US
    GLTO
    +3.39%
    US
    MOVE
    -9.13%
    Invezz·
    US
    GLTO
    +3.39%
    US
    MOVE
    -9.13%

    Shares are trading higher after Galecto announced the completion of its acquisition of Damora Therapeutics.

    benzinga_article·
    US
    GLTO
    +3.39%
    benzinga_article·
    US
    GLTO
    +3.39%
    © 2025 Longbridge｜Disclaimer